May 4, 2009 (FinancialWire) — Inverness Medical Innovations, Inc. (NYSE: IMA) plans to offer $200 million of senior subordinated notes due 2016 in a public offering. UBS Investment Bank (NYSE: UBS), Goldman, Sachs & Co. (NYSE: GS) and Banc of America Securities (NYSE: BAC) will act as joint book-running managers.

Payment of the notes will be guaranteed by certain of Inverness’ domestic subsidiaries. Inverness plans to use the net proceeds from the offering primarily for general corporate purposes.

Waltham, Massachusetts-based Inverness develops diagnosis, monitoring and health management technologies. The company’s products and services, as well as its product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women’s health.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.